Plasticell signs deal stem cell deal with JCR Pharmaceuticals

Published: 25-Feb-2014

Will use its CombiCult stem cell technology to discover custom stem cell culture media

Plasticell, a UK biotechnology company specialising in stem cell differentiation, is to collaborate with JCR Pharmaceuticals of Japan, to discover custom stem cell culture media using its CombiCult stem cell technology.

Financial terms of the agreement have not been disclosed.

'Plasticell’s core capability to provide customers with optimised serum- and xeno-free GMP-grade stem cell differentiation or expansion protocols, which exclude patented factors and contain small molecule substitutes, together with the knowledge we have accumulated from a decade of differentiating all types of stem cells into a multitude of different cell types, has great potential to enhance the competitiveness of the Japanese stem cell effort,' said Dennis Saw, Chief Executive of Plasticell, which is based at Stevenage Bioscience Catalyst in Hertfordshire.

You may also like